SCHEMBL3062076

SCHEMBL3062076

CCOC(=O)c1c(O)c2c([nH]c1=O)C(C)(C)CN(Cc1ccccc1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ADORA1 P30542 1/20 0.44
TRPC5 Q9UL62 1/20 0.39
MAPK1 P28482 2/20 0.39
CASP3 P42574 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
ALDH1A1 P00352 4/20 0.38
TDP2 O95551 1/20 0.38
NSD2 O96028 1/20 0.38
PLCG1 P19174 1/20 0.38
PAX8 Q06710 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910520 0.71 LMNA (0.48) LMNAMAPTMEN1KMT2AADORA1
SCHEMBL2911903 0.71 KDM5A (0.41) LMNAMEN1KMT2ATRPC5KDM4E
SCHEMBL2909839 0.70 GAA (0.45) LMNAMEN1KMT2AKDM4EGAA
SCHEMBL11322118 0.69 LMNA (0.56) LMNAMAPTMEN1KMT2AADORA1
SCHEMBL1174564 0.67 MEN1 (0.47) LMNAMAPTMEN1KMT2AADORA1
SCHEMBL9773708 0.67 CYP3A4 (0.50) LMNAMEN1KMT2AKDM4EGAA
SCHEMBL2274453 0.67 CASP3 (0.47) LMNAMAPTMEN1KMT2AADORA1
SCHEMBL28554924 0.67 LMNA (0.58) LMNAMAPTMEN1KMT2AADORA1
SCHEMBL21621772 0.66 ACHE (0.61) LMNAMAPTKMT2AMAPK1KDM4E
SCHEMBL30570560 0.66 ACHE (0.61) LMNAMAPTKMT2AMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2789338-A2 Condensed pyridine derivate and use thereof Takeda Pharmaceutical Company Limited (JP) 2014-10-15 EP disclosed
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266504-A1 CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF HTR2C, HTR5A, HTR3C LMNA 2182/4885MAPT 4660/4885MEN1 4418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.